Prusoff, W.H.; Lin, T.S.; August, E.M.; Wood, T.G.; Marongiu, M.E. Approaches to antiviral drug development. Yale J. Biol. Med., 1989, 62(2), 215-225.
[PMID: 2773516]

Granich, R.; Williams, B. HIV treatment: Time to lean forward. Lancet, 2016, 387(10013), 27.
[http://dx.doi.org/10.1016/S0140-6736(15)01293-3] [PMID: 26766341]

Long H, Aids. Med. Care, 2012, 916, 874-7720.

Razonable, R.R. Antiviral drugs for viruses other than human immunodeficiency virus. Mayo Clin. Proc., 2011, 86(10), 1009-1026.
[http://dx.doi.org/10.4065/mcp.2011.0309] [PMID: 21964179]

Narang, B.; Grewal, G.; Roy, S.; Bariwal, J.; Gupta, M.; Rawal, R. A novel integrase targeting agent to explore the future prospective of HIV eradication. Dolutegravir. Curr. HIV Res., 2014, 12(5), 325-338.
[http://dx.doi.org/10.2174/1570162X12666140807150753] [PMID: 25106411]

Gallo, R.C.; Montagnier, L. The discovery of HIV as the cause of AIDS. N. Engl. J. Med., 2003, 349(24), 2283-2285.
[http://dx.doi.org/10.1056/NEJMp038194] [PMID: 14668451]

Wei, B.; Han, L.; Abbink, T.E.M.; Groppelli, E.; Lim, D.; Thaker, Y.R.; Gao, W.; Zhai, R.; Wang, J.; Lever, A.; Jolly, C.; Wang, H.; Rudd, C.E. Immune adaptor ADAP in T cells regulates HIV-1 transcription and cell-cell viral spread via different co-receptors. Retrovirology, 2013, 10(1), 101.
[http://dx.doi.org/10.1186/1742-4690-10-101] [PMID: 24047317]

Broder, S.; Fauci, A.S. Progress in drug therapies for HIV infection. Public Health Rep., 1988, 103(3), 224-229.
[PMID: 3131811]

Daluge, S.M.; Martin, M.T.; Sickles, B.R.; Livingston, D.A. An efficient, scalable synthesis of the HIV reverse transcriptase inhibitor Ziagen (1592U89). Nucleosides Nucleotides Nucleic Acids, 2000, 19(1-2), 297-327.
[http://dx.doi.org/10.1080/15257770008033011] [PMID: 10772717]

Perry, C.M.; Noble, S. Didanosine. Drugs, 1999, 58(6), 1099-1135.
[http://dx.doi.org/10.2165/00003495-199958060-00009] [PMID: 10651392]

Patel, M.; Ko, S.S.; McHugh, R.J., Jr; Markwalder, J.A.; Srivastava, A.S.; Cordova, B.C.; Klabe, R.M.; Erickson-Viitanen, S.; Trainor, G.L.; Seitz, S.P. Synthesis and evaluation of analogs of Efavirenz (SUSTIVATM) as HIV-1 reverse transcriptase inhibitors. Bioorg. Med. Chem. Lett., 1999, 9(19), 2805-2810.
[http://dx.doi.org/10.1016/S0960-894X(99)00486-2] [PMID: 10522695]

Penazzato, M.; Giaquinto, C. Role of non-nucleoside reverse transcriptase inhibitors in treating HIV-infected children. Drugs, 2011, 71(16), 2131-2149.
[http://dx.doi.org/10.2165/11597680-000000000-00000] [PMID: 22035514]

INTELENCE® (etravirine) [Tablets]. Prescribing information. Available From: http://www.fda.gov/cder/foi/label/2008/0221871b1.pdf (Accessed 20 Sept 2008).

Swainston Harrison, T.; Scott, L.J. Atazanavir. Drugs, 2005, 65(16), 2309-2336.
[http://dx.doi.org/10.2165/00003495-200565160-00010] [PMID: 16266202]

Prezista. 2008. Available From: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021976s021lbl.pdf

Pham, P. Drug profile: fosamprenavir (Lexiva). The Hopkins HIV report: A bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service, 2003, 15(6), 10-11.

Williams, I.G. Enfuvirtide (Fuzeon): The first fusion inhibitor. Int. J. Clin. Pract., 2003, 57(10), 890-897.
[http://dx.doi.org/10.1111/j.1742-1241.2003.tb10637.x] [PMID: 14712892]

Kuritzkes, D.; Kar, S.; Kirkpatrick, P. Maraviroc. Nat. Rev. Drug Discov., 2008, 7(1), 15-16.
[http://dx.doi.org/10.1038/nrd2490] [PMID: 19008887]

Deeks, E.D. Cobicistat: A review of its use as a pharmacokinetic enhancer of atazanavir and darunavir in patients with HIV-1 infection. Drugs, 2014, 74(2), 195-206.
[http://dx.doi.org/10.1007/s40265-013-0160-x] [PMID: 24343782]

Xu, L.; Liu, H.; Murray, B.P.; Callebaut, C.; Lee, M.S.; Hong, A.; Strickley, R.G.; Tsai, L.K.; Stray, K.M.; Wang, Y.; Rhodes, G.R.; Desai, M.C. Cobicistat (GS-9350): A potent and selective inhibitor of human CYP3A as a novel pharmacoenhancer. ACS Med. Chem. Lett., 2010, 1(5), 209-213.
[http://dx.doi.org/10.1021/ml1000257] [PMID: 24900196]

Clayden, P.; Collins, S.; Frick, M.; Harrington, M.; Horn, T.; Jefferys, R.; Lessem, E.; McKenna, L.; Swan, T. 2021 Pipeline Report: HIV, Hepatitis C Virus (HCV), and Tuberculosis Drugs, Diagnostics, Vaccines, Preventive Technologies, Research Toward a Cure, and Immune- Based and Gene Therapies in Development; New York; , 2015.

Hossain, M.A. New drugs approval. Bangladesh Pharma. J., 2015, 18(1), 83-84.
[http://dx.doi.org/10.3329/bpj.v18i1.23524]

Podzamczer, D.; Ferrer, E.; Consiglio, E.; Gatell, J.M.; Perez, P.; Perez, J.L.; Luna, E.; González, A.; Pedrol, E.; Lozano, L.; Ocaña, I.; Llibre, J.M.; Casiró, A.; Aranda, M.; Barrufet, P.; Martínez-Lacasa, J.; Miró, J.M.; Badía, X.; Casado, A.; Lupo, S.; Cahn, P.; Maños, M.; Estela, J.; Barberá, M.J.; Santín, M.; Gudiol, F.; Hidalgo, M.; Knobel, H.; Azuaje, C.; Ribera, E.; Roget, M.; Force, L.; Dalmau, D.; Suarez, C. A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study). Antivir. Ther., 2002, 7(2), 81-90.
[http://dx.doi.org/10.1177/135965350200700202] [PMID: 12212928]

John, M.; McKinnon, E.J.; James, I.R.; Nolan, D.A.; Herrmann, S.E.; Moore, C.B.; White, A.J.; Mallal, S.A. Randomized, controlled, 48-week study of switching stavudine and/or protease inhibitors to combivir/abacavir to prevent or reverse lipoatrophy in HIV-infected patients. J. Acquir. Immune Defic. Syndr., 2003, 33(1), 29-33.
[http://dx.doi.org/10.1097/00126334-200305010-00005] [PMID: 12792352]

Corbett, A.H.; Lim, M.L.; Kashuba, A.D.M. Kaletra (lopinavir/ritonavir). Ann. Pharmacother., 2002, 36(7-8), 1193-1203.
[http://dx.doi.org/10.1345/aph.1A363] [PMID: 12086554]

Seaton, O.R.A.; Fox, R.; Bodasing, N.; Peters, S.E.; Gourlay, Y. Effect of co-formulated zidovudine, lamivudine and abacavir (Trizivir) on antiretroviral-naive patients presenting with advanced HIV-1 infection. AIDS, 2003, 17(3), 445-447.
[http://dx.doi.org/10.1097/00002030-200302140-00021] [PMID: 12556701]

Shey, M.; Kongnyuy, E.J.; Shang, J.; Wiysonge, C.S. A combination drug of abacavir-lamivudine-zidovudine (Trizivir) for treating HIV infection and AIDS. Cochrane Database Syst. Rev., 2009.(3), CD005481.
[PMID: 19588374] [http://dx.doi.org/10.1002/14651858.CD005481.pub2.]

Camp, R. Epzicom Brand Abacavir-Lamivudine QD; Treatment Action Group, 2004.

James, J.S. FDA approves two combination pills, Epzicom and Truvada; comment on commercial race to once-a-day nucleosides. AIDS Treat. News, 2004, (403), 6.
[PMID: 15386855]

De Clercq, E. From adefovir to Atripla™ via tenofovir, Viread™ and Truvada™. Future Virol., 2006, 1(6), 709-715.
[http://dx.doi.org/10.2217/17460794.1.6.709]

García-Lerma, J.G.; Cong, M.; Mitchell, J.; Youngpairoj, A.S.; Zheng, Q.; Masciotra, S.; Martin, A.; Kuklenyik, Z.; Holder, A.; Lipscomb, J.; Pau, C.P.; Barr, J.R.; Hanson, D.L.; Otten, R.; Paxton, L.; Folks, T.M.; Heneine, W. Intermittent prophylaxis with oral truvada protects macaques from rectal SHIV infection. Sci. Transl. Med., 2010, 2(14), 14ra4.
[http://dx.doi.org/10.1126/scitranslmed.3000391] [PMID: 20371467]

Deeks, E.D.; Perry, C.M. Efavirenz/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen (Atripla®): A review of its use in the management of HIV infection. Drugs, 2010, 70(17), 2315-2338.
[http://dx.doi.org/10.2165/11203800-000000000-00000] [PMID: 21080746]

Kabbara, W.K.; Ramadan, W.H. Emtricitabine/rilpivirine/tenofovir disoproxil fumarate for the treatment of HIV-1 infection in adults. J. Infect. Public Health, 2015, 8(5), 409-417.
[http://dx.doi.org/10.1016/j.jiph.2015.04.020] [PMID: 26001757]

Bernardini, C.; Maggiolo, F. Triple-combination rilpivirine, emtricitabine, and tenofovir (Complera™/Eviplera™) in the treatment of HIV infection. Patient Prefer. Adherence, 2013, 7, 531-542.
[PMID: 23814462]

Breeze, S. Novel HIV-1 treatment Stribild™ gains regulatory approval. Expert Rev. Clin. Pharmacol., 2012, 5(6), 613.
[PMID: 23234321]

Olin, J.L.; Spooner, L.M.; Klibanov, O.M. Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate single tablet for HIV-1 infection treatment. Ann. Pharmacother., 2012, 46(12), 1671-1677.
[http://dx.doi.org/10.1345/aph.1R468] [PMID: 23136357]

McKeage, K.; Perry, C.M.; Keam, S.J. Darunavir. Drugs, 2009, 69(4), 477-503.
[http://dx.doi.org/10.2165/00003495-200969040-00007] [PMID: 19323590]

Astuti, N.; Maggiolo, F. Single-tablet regimens in HIV therapy. Infect. Dis. Ther., 2014, 3(1), 1-17.
[http://dx.doi.org/10.1007/s40121-014-0024-z] [PMID: 25134808]

DeJesus, E.; Rockstroh, J.K.; Henry, K.; Molina, J.M.; Gathe, J.; Ramanathan, S.; Wei, X.; Yale, K.; Szwarcberg, J.; White, K.; Cheng, A.K.; Kearney, B.P. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: A randomised, double-blind, phase 3, non-inferiority trial. Lancet, 2012, 379(9835), 2429-2438.
[http://dx.doi.org/10.1016/S0140-6736(12)60918-0] [PMID: 22748590]

Gunawardana, M.; Remedios-Chan, M.; Miller, C.S.; Fanter, R.; Yang, F.; Marzinke, M.A.; Hendrix, C.W.; Beliveau, M.; Moss, J.A.; Smith, T.J.; Baum, M.M. Pharmacokinetics of long-acting tenofovir alafenamide (GS-7340) subdermal implant for HIV prophylaxis. Antimicrob. Agents Chemother., 2015, 59(7), 3913-3919.
[http://dx.doi.org/10.1128/AAC.00656-15] [PMID: 25896688]

Fellner, C. pharmaceutical approval update. P&T, 2016, 41(4), 220-221.
[PMID: 27069339]

Kalapila, A.G.; Marrazzo, J. antiretroviral therapy for prevention of human immunodeficiency virus infection. Med. Clin. North Am., 2016, 100(4), 927-950.
[http://dx.doi.org/10.1016/j.mcna.2016.03.013] [PMID: 27235622]

Hosein, S.R. Descovy Approved in Canada--Key Information. Canadian AIDS Treatment Information Exchange. 2016. Available From: http://www.thebodypro.com/content/77574/descovy-approved-in-canada--key-information.html (Accessed: May 10, 2016).

Artacho, M.Á.; Barreiro, P.; Fernández-Montero, J.V. Long-term treatment of patients with HIV-1: The role of atazanavir. HIV AIDS (Auckl.), 2010, 2, 157-166.
[PMID: 22096394]

Babu, V.V.R.; Sharma, P.K.; Singhvi, I. A new gradient liquid chromatographic method for simultaneous estimation of tenofovir diisoproxil fumarate, cobicistat, emtricitabine and elvitegravir in bulk drug and tablet dosage form. Asian J. Chem., 2014, 26(18), 6233-6237.
[http://dx.doi.org/10.14233/ajchem.2014.17196]

Ding, H.X.; Leverett, C.A.; Kyne, R.E., Jr; Liu, K.K.C.; Fink, S.J.; Flick, A.C.; O’Donnell, C.J. Synthetic approaches to the 2013 new drugs. Bioorg. Med. Chem., 2015, 23(9), 1895-1922.
[http://dx.doi.org/10.1016/j.bmc.2015.02.056] [PMID: 25797159]

Han, J.; Konno, H.; Sato, T.; Soloshonok, V.A.; Izawa, K. Tailor-made amino acids in the design of small-molecule blockbuster drugs. Eur. J. Med. Chem., 2021, 220, 113448.
[http://dx.doi.org/10.1016/j.ejmech.2021.113448] [PMID: 33906050]

Fan, X.; Song, Y.L.; Long, Y.Q. An efficient and practical synthesis of the HIV protease inhibitor Atazanavir via a highly diastereoselective reduction approach. Org. Process Res. Dev., 2008, 12(1), 69-75.
[http://dx.doi.org/10.1021/op7001563]

von Hentig, N. Clinical use of cobicistat as a pharmacoenhancer of human immunodeficiency virus therapy. HIV AIDS (Auckl.), 2015, 8, 1-16.
[http://dx.doi.org/10.2147/HIV.S70836] [PMID: 26730211]

Lepist, E.I.; Phan, T.K.; Roy, A.; Tong, L.; MacLennan, K.; Murray, B.; Ray, A.S. Cobicistat boosts the intestinal absorption of transport substrates, including HIV protease inhibitors and GS-7340, in vitro. Antimicrob. Agents Chemother., 2012, 56(10), 5409-5413.
[http://dx.doi.org/10.1128/AAC.01089-12] [PMID: 22850510]

López-Cortés, L.F. [Pharmacology, pharmacokinetic features and interactions of atazanavir] Enferm. Infecc. Microbiol. Clin., 2008, 26(Suppl. 17), 2-8.
[PMID: 20116610]

Hossain, M.A.; Tran, T.; Chen, T.; Mikus, G.; Greenblatt, D.J. Inhibition of human cytochromes P450 in vitro by ritonavir and cobicistat. J. Pharm. Pharmacol., 2017, 69(12), 1786-1793.
[http://dx.doi.org/10.1111/jphp.12820] [PMID: 28960344]

a) Tseng, A.; Hughes, C.A.; Wu, J.; Seet, J.; Phillips, E.J. Cobicistat versus Ritonavir: Similar pharmacokinetic enhancers but some important differences. Ann. Pharmacother., 2017, 51(11), 1008-1022.
[http://dx.doi.org/10.1177/1060028017717018] [PMID: 28627229];
b) EVOTAZ 300 Mg/150 Mg film-coated tablets - Summary of product characteristics. Available From: https://www.medicines.org.uk/emc/medicine/30707 (Accessed 08 Oct 2019). ;
c) Evotaz, FDA Label - Tablet. National Institutes of Health, U.S. Department of Health and Human Services. Available From: https://aidsinfo.nih.gov/drugs/537/evotaz/175/professional (Accessed 08 Oct 2019).

DeJesus, E.; Rockstroh, J.; Henry, K. Efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir DF (Quad) compared to ritonavir-boosted atazanavir plus emtricitabine/tenofovir DF in treatment naive HIV-1 infected subjects. Confe. Retrov. Oppor. Infec, 2012, 3.

Sax, P.; DeJesus, E.; Mills, A. Elvitegravir/cobicistat/emtricitabine/tenofovir (Quad) has non-inferior efficacy and favorable safety compared to efavirenz/emtricitabine/tenofovir in treatment-naïve HIV-1+subjects. Conference on Retroviruses and Opportunistic Infections March 2012Seattle, WA , 2012.

Margot, N.A.; Kitrinos, K.M.; Fordyce, M.; McCallister, S.; Miller, M.D.; Callebaut, C. Rare emergence of drug resistance in HIV-1 treatment -naïve patients after 48 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide. HIV Clin. Trials, 2016, 17(2), 78-87.
[http://dx.doi.org/10.1080/15284336.2016.1142731] [PMID: 26892863]

Colonno, R.; Rose, R.; McLaren, C.; Thiry, A.; Parkin, N.; Friborg, J. Identification of I50L as the signature atazanavir (ATV)-resistance mutation in treatment-naive HIV-1-infected patients receiving ATV-containing regimens. J. Infect. Dis., 2004, 189(10), 1802-1810.
[http://dx.doi.org/10.1086/386291] [PMID: 15122516]

Brenner, B.G.; Coutsinos, D. The K65R mutation in HIV-1 reverse transcriptase: Genetic barriers, resistance profile and clinical implications. HIV Ther., 2009, 3(6), 583-594.
[http://dx.doi.org/10.2217/hiv.09.40] [PMID: 20190870]

Achenbach, C.J.; Darin, K.M.; Murphy, R.L.; Katlama, C. Atazanavir/ritonavir-based combination antiretroviral therapy for treatment of HIV-1 infection in adults. Future Virol., 2011, 6(2), 157-177.
[http://dx.doi.org/10.2217/fvl.10.89] [PMID: 21731578]

Gianotti, N.; Guffanti, M.; Galli, L.; Margonato, A.; Chiaravalli, G.; Bigoloni, A.; Lazzarin, A.; Castagna, A. Electrocardiographic changes in HIV-infected, drug-experienced patients being treated with atazanavir. AIDS, 2007, 21(12), 1648-1651.
[http://dx.doi.org/10.1097/QAD.0b013e32826fbc6a] [PMID: 17630564]

Song, I.; Borland, J.; Chen, S.; Lou, Y.; Peppercorn, A.; Wajima, T.; Min, S.; Piscitelli, S.C. Effect of atazanavir and atazanavir/ritonavir on the pharmacokinetics of the next-generation HIV integrase inhibitor, S/GSK1349572. Br. J. Clin. Pharmacol., 2011, 72(1), 103-108.
[http://dx.doi.org/10.1111/j.1365-2125.2011.03947.x] [PMID: 21342217]

Sevinsky, H.; Tao, X.; Wang, R.; Ravindran, P.; Sims, K.; Xu, X.; Jariwala, N.; Bertz, R. A randomized trial in healthy subjects to assess the bioequivalence of an atazanavir/cobicistat fixed-dose combination tablet versus administration as separate agents. Antivir. Ther., 2015, 20(5), 493-500.
[http://dx.doi.org/10.3851/IMP2913] [PMID: 25361436]

Barrail-Tran, A.; Mentré, F.; Cosson, C.; Piketty, C.; Chazallon, C.; Gérard, L.; Girard, P.M.; Taburet, A.M. Influence of alpha-1 glycoprotein acid concentrations and variants on atazanavir pharmacokinetics in HIV-infected patients included in the ANRS 107 trial. Antimicrob. Agents Chemother., 2010, 54(2), 614-619.
[http://dx.doi.org/10.1128/AAC.00797-09] [PMID: 19995932]

Wempe, M.F.; Anderson, P.L. Atazanavir metabolism according to CYP3A5 status: An in vitro-in vivo assessment. Drug Metab. Dispos., 2011, 39(3), 522-527.
[http://dx.doi.org/10.1124/dmd.110.036178] [PMID: 21148251]

Shimpi, S. Bioequivalence Study Recommendation for Atazanavir Sulfate Capsules by US FDA and a Contrary View, 2012, 1, 388.

Crutchley, R.D.; Cheng, A.; Guduru, R. Evaluating the role of atazanavir/cobicistat and darunavir/cobicistat fixed-dose combinations for the treatment of HIV-1 infection. HIV AIDS, 2016, 8(8), 47-65.
[http://dx.doi.org/10.2147/HIV.S99063] [PMID: 27022304]

a) Pawar, S.; Kumawat, M.K.; Kundu, M.; Kumar, K. Synthetic and medicinal perspective of antileishmanial agents: An overview. J. Mol. Struct., 2023, 1271, 133977.
[http://dx.doi.org/10.1016/j.molstruc.2022.133977];
b) Rathod, B.; Kumar, K. Synthetic and medicinal perspective of 1,2,4-triazole as anticancer agents. Chem. Biodivers., 2022, 19(11), e202200679.
[http://dx.doi.org/10.1002/cbdv.202200679] [PMID: 36226542];
c) Konar, D.; Maru, S.; Kar, S.; Kumar, K. Synthesis and clinical development of Palbociclib: An overview. Med. Chem., 2022, 18(1), 2-25.
[http://dx.doi.org/10.2174/1573406417666201204161243] [PMID: 33280599];
d) Pawar, S.; Kumar, K.; Gupta, M.K.; Rawal, R.K. Synthetic and medicinal perspective of fused-thiazoles as anticancer agents. Anticancer. Agents Med. Chem., 2021, 21(11), 1379-1402.
[http://dx.doi.org/10.2174/1871520620666200728133017] [PMID: 32723259];
e) Kaur, R.; Kumar, K. Synthetic and medicinal perspective of quinolines as antiviral agents. Eur. J. Med. Chem., 2021, 215, 113220-113258.
[http://dx.doi.org/10.1016/j.ejmech.2021.113220] [PMID: 33609889];
f) Kapoor, Y.; Kumar, K. Structural and clinical impact of anti-allergy agents: An overview. Bioorg. Chem., 2020, 94, 103351-103375.
[http://dx.doi.org/10.1016/j.bioorg.2019.103351] [PMID: 31668464];
g) Kaur, R.; Manjal, S.K.; Rawal, R.K.; Kumar, K. Recent synthetic and medicinal perspectives of tryptanthrin. Bioorg. Med. Chem., 2017, 25(17), 4533-4552.
[http://dx.doi.org/10.1016/j.bmc.2017.07.003] [PMID: 28720329];
h) Kaur Manjal, S.; Kaur, R.; Bhatia, R.; Kumar, K.; Singh, V.; Shankar, R.; Kaur, R.; Rawal, R.K. Synthetic and medicinal perspective of thiazolidinones: A review. Bioorg. Chem., 2017, 75, 406-423.
[http://dx.doi.org/10.1016/j.bioorg.2017.10.014] [PMID: 29102723];
i) Kaur, R.; Chaudhary, S.; Kumar, K.; Gupta, M.K.; Rawal, R.K. Recent synthetic and medicinal perspectives of dihydropyrimidinones: A review. Eur. J. Med. Chem., 2017, 132, 108-134.
[http://dx.doi.org/10.1016/j.ejmech.2017.03.025] [PMID: 28342939];
j) Kumar, B.; Singh, V.; Shankar, R.; Kumar, K.; Rawal, R. Synthetic and medicinal prospective of structurally modified curcumins. Curr. Top. Med. Chem., 2016, 17(2), 148-161.
[http://dx.doi.org/10.2174/1568026616666160605050052] [PMID: 27280465];
k) Mittal, M.; Kumar, K.; Anghore, D.; Rawal, R.K. ICP-MS: Analytical method for identification and detection of elemental impurities. Curr. Drug Discov. Technol., 2017, 14(2), 106-120.
[http://dx.doi.org/10.2174/1570163813666161221141402] [PMID: 28003007];
l) Talwan, P.; Choudhary, S.; Kumar, K.; Rawal, R.K. Chemical and medicinal versatility of substituted 1, 4-dihydropyridines. Curr. Bioact. Compd., 2017, 13, 109-120.
[http://dx.doi.org/10.2174/1573407212666160607090202]

Puri, S.; Ahmad, I.; Patel, H.; Kumar, K.; Juvale, K. Evaluation of oxindole derivatives as a potential anticancer agent against breast carcinoma cells: In vitro, in silico and molecular docking study. Toxicol in vitro. 2023, 86, 105517.;
b) Kumawat, K; Kaur, R.; Kumar, K. In-silico prediction of novel fused quinazoline based topoisomerase inhibitors as anticancer agents. Med. Chem., 2023, 19, 431-444.